{"relation": "INHIBITOR", "token": ["Moreover, the rank order for potency in inhibiting ", "acetylcholinesterase", " (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>", "parathion", ">gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent."], "h": {"pos": [1, 2], "type": null, "name": "acetylcholinesterase  (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>"}, "t": {"pos": [3, 4], "type": null, "name": "parathion >gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent."}}
{"relation": "INHIBITOR", "token": ["The most potent in\u2005vitro DASI discovered is an ", "imidazole", " derivative with IC50 values against aromatase and ", "steroid sulfatase", " in a JEG-3 cell preparation of 0.2 and 2.5\u2005nM, respectively."], "h": {"pos": [1, 2], "type": null, "name": "imidazole  derivative with IC50 values against aromatase and "}, "t": {"pos": [3, 4], "type": null, "name": "steroid sulfatase  in a JEG-3 cell preparation of 0.2 and 2.5\u2005nM, respectively."}}
{"relation": "INHIBITOR", "token": ["", "Beta-glucogallin", " reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of ", "aldose reductase", " in murine macrophages and ocular tissues."], "h": {"pos": [1, 2], "type": null, "name": "Beta-glucogallin  reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of "}, "t": {"pos": [3, 4], "type": null, "name": "aldose reductase  in murine macrophages and ocular tissues."}}
{"relation": "INHIBITOR", "token": ["A series of xanthine derivatives in which a methylene was inserted at position 8 of ", "xanthine", " scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (", "DPP-4", ") for the treatment of type 2 diabetes."], "h": {"pos": [1, 2], "type": null, "name": "xanthine  scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 ("}, "t": {"pos": [3, 4], "type": null, "name": "DPP-4 ) for the treatment of type 2 diabetes."}}
{"relation": "INHIBITOR", "token": ["The cytosine analog ", "5-aza-2'-deoxycytidine", " (decitabine) hypomethylates DNA by inhibiting ", "DNA methyltransferase", "."], "h": {"pos": [1, 2], "type": null, "name": "5-aza-2'-deoxycytidine  (decitabine) hypomethylates DNA by inhibiting "}, "t": {"pos": [3, 4], "type": null, "name": "DNA methyltransferase ."}}
{"relation": "INHIBITOR", "token": ["", "Etoposide", " (VP-16) is a topoisomerase-II (", "topo II", ") inhibitor chemotherapeutic agent."], "h": {"pos": [1, 2], "type": null, "name": "Etoposide  (VP-16) is a topoisomerase-II ("}, "t": {"pos": [3, 4], "type": null, "name": "topo II ) inhibitor chemotherapeutic agent."}}
{"relation": "INHIBITOR", "token": ["These results suggest that ", "gemfibrozil", " inhibits the induction of ", "iNOS", " probably by inhibiting the activation of NF-kappaB, AP-1, and C/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases."], "h": {"pos": [1, 2], "type": null, "name": "gemfibrozil  inhibits the induction of "}, "t": {"pos": [3, 4], "type": null, "name": "iNOS  probably by inhibiting the activation of NF-kappaB, AP-1, and C/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases."}}
{"relation": "INHIBITOR", "token": ["Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the ", "MAO", " inhibitory properties of a series of phthalide ", " 2-benzofuran-1(3H)-one", "] analogues."], "h": {"pos": [1, 2], "type": null, "name": "MAO  inhibitory properties of a series of phthalide "}, "t": {"pos": [3, 4], "type": null, "name": " 2-benzofuran-1(3H)-one ] analogues."}}
{"relation": "INHIBITOR", "token": ["Both ", "NS-398", " and Dup-697 exhibited time-dependent inactivation of ", "hCOX-2", ", as did indomethacin on both enzymes."], "h": {"pos": [1, 2], "type": null, "name": "NS-398  and Dup-697 exhibited time-dependent inactivation of "}, "t": {"pos": [3, 4], "type": null, "name": "hCOX-2 , as did indomethacin on both enzymes."}}
{"relation": "INHIBITOR", "token": ["Inhibition of ", "p95ErbB2", ", p185ErbB2, and EGFR phosphorylation by ", "GW572016", " resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels."], "h": {"pos": [1, 2], "type": null, "name": "p95ErbB2 , p185ErbB2, and EGFR phosphorylation by "}, "t": {"pos": [3, 4], "type": null, "name": "GW572016  resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels."}}
{"relation": "INHIBITOR", "token": ["However, despite activation of L-arginine uptake, the inhibition of ", "arginase", " activity by ", "Nor-NOHA", " was still significant."], "h": {"pos": [1, 2], "type": null, "name": "arginase  activity by "}, "t": {"pos": [3, 4], "type": null, "name": "Nor-NOHA  was still significant."}}
{"relation": "INHIBITOR", "token": ["In this report, we show that the hypolipidemic agent ", "atorvastatin", " is a competitive inhibitor of ", "porcine DPP-IV", " in vitro, with K(i)=57.8+/-2.3 microM."], "h": {"pos": [1, 2], "type": null, "name": "atorvastatin  is a competitive inhibitor of "}, "t": {"pos": [3, 4], "type": null, "name": "porcine DPP-IV  in vitro, with K(i)=57.8+/-2.3 microM."}}
{"relation": "INHIBITOR", "token": ["Indomethacin abolished the inhibitory effect of ", "acetazolamide", " on CA I and ", "CA II", "."], "h": {"pos": [1, 2], "type": null, "name": "acetazolamide  on CA I and "}, "t": {"pos": [3, 4], "type": null, "name": "CA II ."}}
{"relation": "INHIBITOR", "token": ["In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, ", "sorafenib", " blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as ", "extracellular signal-regulated kinase1/2", " and Stat5 phosphorylation."], "h": {"pos": [1, 2], "type": null, "name": "sorafenib  blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as "}, "t": {"pos": [3, 4], "type": null, "name": "extracellular signal-regulated kinase1/2  and Stat5 phosphorylation."}}
{"relation": "INHIBITOR", "token": ["First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive ", "TOP2", " poisons (e.g. amonafide, ", "batracylin", ", and menadione) was only slightly (less than 3-fold) affected."], "h": {"pos": [1, 2], "type": null, "name": "TOP2  poisons (e.g. amonafide, "}, "t": {"pos": [3, 4], "type": null, "name": "batracylin , and menadione) was only slightly (less than 3-fold) affected."}}
{"relation": "INHIBITOR", "token": ["", "Sorafenib", " inhibited the kinase activity of both ", "C-RAF", " and B-RAF (wild type and V600E mutant)."], "h": {"pos": [1, 2], "type": null, "name": "Sorafenib  inhibited the kinase activity of both "}, "t": {"pos": [3, 4], "type": null, "name": "C-RAF  and B-RAF (wild type and V600E mutant)."}}
{"relation": "INHIBITOR", "token": ["A series of ", "pyrido-quinazolines", " have been synthesised, characterised and tested for their in vitro ", "EGFR", " tyrosine kinase inhibitory activity."], "h": {"pos": [1, 2], "type": null, "name": "pyrido-quinazolines  have been synthesised, characterised and tested for their in vitro "}, "t": {"pos": [3, 4], "type": null, "name": "EGFR  tyrosine kinase inhibitory activity."}}
{"relation": "ANTAGONIST", "token": ["", "Alprenolol", " and BAAM also caused surmountable antagonism of isoprenaline responses, and this ", "beta 1-adrenoceptor", " antagonism was slowly reversible."], "h": {"pos": [1, 2], "type": null, "name": "Alprenolol  and BAAM also caused surmountable antagonism of isoprenaline responses, and this "}, "t": {"pos": [3, 4], "type": null, "name": "beta 1-adrenoceptor  antagonism was slowly reversible."}}
{"relation": "ANTAGONIST", "token": ["Although generally highly specific for ", "angiotensin II type 1 receptors", ", some ARBs, particularly ", "telmisartan", ", are partial agonists at peroxisome proliferator-activated receptor-\u03b3."], "h": {"pos": [1, 2], "type": null, "name": "angiotensin II type 1 receptors , some ARBs, particularly "}, "t": {"pos": [3, 4], "type": null, "name": "telmisartan , are partial agonists at peroxisome proliferator-activated receptor-\u03b3."}}
{"relation": "ANTAGONIST", "token": ["", "Nizatidine", " (LY139037), a selective ", "histamine H2-receptor", " antagonist, is a potent inhibitor of gastric acid secretion."], "h": {"pos": [1, 2], "type": null, "name": "Nizatidine  (LY139037), a selective "}, "t": {"pos": [3, 4], "type": null, "name": "histamine H2-receptor  antagonist, is a potent inhibitor of gastric acid secretion."}}
{"relation": "AGONIST", "token": ["The use of ", "A3 receptor", " agonist ", "IB-MECA", " attenuates EAP."], "h": {"pos": [1, 2], "type": null, "name": "A3 receptor  agonist "}, "t": {"pos": [3, 4], "type": null, "name": "IB-MECA  attenuates EAP."}}
{"relation": "AGONIST", "token": ["While there is considerable indirect evidence to implicate ", "histamine", " in the pathogenesis of asthma, a critical evaluation of ", "H1-receptor", " antagonism in this condition has, until recently, proved difficult, as many of the early H1-receptor antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity."], "h": {"pos": [1, 2], "type": null, "name": "histamine  in the pathogenesis of asthma, a critical evaluation of "}, "t": {"pos": [3, 4], "type": null, "name": "H1-receptor  antagonism in this condition has, until recently, proved difficult, as many of the early H1-receptor antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity."}}
{"relation": "DOWNREGULATOR", "token": ["CRH caused a rise in plasma ACTH after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of ", "CRH", "-induced ACTH secretion was significantly lower after ", "loperamide", "."], "h": {"pos": [1, 2], "type": null, "name": "CRH -induced ACTH secretion was significantly lower after "}, "t": {"pos": [3, 4], "type": null, "name": "loperamide ."}}
{"relation": "DOWNREGULATOR", "token": ["Treatment of C57 BL/6 mice with ", "bleomycin", " increased fibroblast viability and collagen production and significantly downregulated ", "Nrf2", "."], "h": {"pos": [1, 2], "type": null, "name": "bleomycin  increased fibroblast viability and collagen production and significantly downregulated "}, "t": {"pos": [3, 4], "type": null, "name": "Nrf2 ."}}
{"relation": "PRODUCT-OF", "token": ["Inhibition of ", "S-adenosylmethionine decarboxylase", " by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and ", "spermine", " with a significant accumulation of putrescine and induction of ODC."], "h": {"pos": [1, 2], "type": null, "name": "S-adenosylmethionine decarboxylase  by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and "}, "t": {"pos": [3, 4], "type": null, "name": "spermine  with a significant accumulation of putrescine and induction of ODC."}}
{"relation": "PRODUCT-OF", "token": ["Reduced synthesis of nitric oxide (", "NO", ") contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of ", "constitutive nitric-oxide synthase", " (NOS) and cytosolic arginase I and mitochondrial arginase II."], "h": {"pos": [1, 2], "type": null, "name": "NO ) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of "}, "t": {"pos": [3, 4], "type": null, "name": "constitutive nitric-oxide synthase  (NOS) and cytosolic arginase I and mitochondrial arginase II."}}
{"relation": "PRODUCT-OF", "token": ["The ratio between the GDC/", "SHMT", " and C1-THF synthase/SHMT pathways of ", "Ser", " synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1."], "h": {"pos": [1, 2], "type": null, "name": "SHMT  and C1-THF synthase/SHMT pathways of "}, "t": {"pos": [3, 4], "type": null, "name": "Ser  synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1."}}
{"relation": "SUBSTRATE", "token": ["Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and ", "4-methoxy-2-naphthylamide", " of L-arginine for ", "aminopeptidase B", "."], "h": {"pos": [1, 2], "type": null, "name": "4-methoxy-2-naphthylamide  of L-arginine for "}, "t": {"pos": [3, 4], "type": null, "name": "aminopeptidase B ."}}
{"relation": "SUBSTRATE", "token": ["In relation to zinc bioavailability, \u03b1-CPPs, \u03b2-CPPs, \u03b1(s1)-CN(64-74)4P and ", "\u03b2-CN", "(1-25)4P increased ", "zinc", " uptake."], "h": {"pos": [1, 2], "type": null, "name": "\u03b2-CN (1-25)4P increased "}, "t": {"pos": [3, 4], "type": null, "name": "zinc  uptake."}}
{"relation": "SUBSTRATE", "token": ["In relation to zinc bioavailability, \u03b1-CPPs, ", "\u03b2-CPPs", ", \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased ", "zinc", " uptake."], "h": {"pos": [1, 2], "type": null, "name": "\u03b2-CPPs , \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased "}, "t": {"pos": [3, 4], "type": null, "name": "zinc  uptake."}}
{"relation": "SUBSTRATE", "token": ["Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed ", "5-MeO-DMT", " metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-", "CYP2D6", " mouse models."], "h": {"pos": [1, 2], "type": null, "name": "5-MeO-DMT  metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-"}, "t": {"pos": [3, 4], "type": null, "name": "CYP2D6  mouse models."}}
{"relation": "SUBSTRATE", "token": ["Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to ", "arginine", " depletion with ", "arginine-depleting enzymes", "."], "h": {"pos": [1, 2], "type": null, "name": "arginine  depletion with "}, "t": {"pos": [3, 4], "type": null, "name": "arginine-depleting enzymes ."}}
{"relation": "INDIRECT-UPREGULATOR", "token": ["There was also an increase in c-kit, Trio, Rho-A, ", "Rac-3", ", EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the ", "parathion", "-treated cells."], "h": {"pos": [1, 2], "type": null, "name": "Rac-3 , EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the "}, "t": {"pos": [3, 4], "type": null, "name": "parathion -treated cells."}}
{"relation": "INDIRECT-UPREGULATOR", "token": ["Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of ", "cytochrome c", " to the cytosol induced by ", "DZN", "."], "h": {"pos": [1, 2], "type": null, "name": "cytochrome c  to the cytosol induced by "}, "t": {"pos": [3, 4], "type": null, "name": "DZN ."}}
{"relation": "INDIRECT-UPREGULATOR", "token": ["", "Leukotriene D4", " induces cognitive impairment through enhancement of CysLT\u2081 R-mediated ", "amyloid-\u03b2", " generation in mice."], "h": {"pos": [1, 2], "type": null, "name": "Leukotriene D4  induces cognitive impairment through enhancement of CysLT\u2081 R-mediated "}, "t": {"pos": [3, 4], "type": null, "name": "amyloid-\u03b2  generation in mice."}}
{"relation": "INDIRECT-UPREGULATOR", "token": ["Results showed that neonatal ", "quinpirole", " treatment induced ", "D2", " priming that was eliminated by olanzapine treatment."], "h": {"pos": [1, 2], "type": null, "name": "quinpirole  treatment induced "}, "t": {"pos": [3, 4], "type": null, "name": "D2  priming that was eliminated by olanzapine treatment."}}
{"relation": "UPREGULATOR", "token": ["Saturated ", "palmitic and stearic acids", " increased ceramides, up-regulated ", "PTP1B", ", and had AKt and PTP1B phosphorylation at Ser 50 impaired."], "h": {"pos": [1, 2], "type": null, "name": "palmitic and stearic acids  increased ceramides, up-regulated "}, "t": {"pos": [3, 4], "type": null, "name": "PTP1B , and had AKt and PTP1B phosphorylation at Ser 50 impaired."}}
{"relation": "INDIRECT-DOWNREGULATOR", "token": ["The inhibition of UG synthesis and ", "PR", " down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these ", "NET", " metabolites possess antiprogestational properties."], "h": {"pos": [1, 2], "type": null, "name": "PR  down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these "}, "t": {"pos": [3, 4], "type": null, "name": "NET  metabolites possess antiprogestational properties."}}
{"relation": "INDIRECT-DOWNREGULATOR", "token": ["In addition, we found that ", "neoechinulin A", " significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (", "IL-6", "), and prostaglandin E2 (PGE2) in activated BV-2 cells."], "h": {"pos": [1, 2], "type": null, "name": "neoechinulin A  significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 ("}, "t": {"pos": [3, 4], "type": null, "name": "IL-6 ), and prostaglandin E2 (PGE2) in activated BV-2 cells."}}
{"relation": "INDIRECT-DOWNREGULATOR", "token": ["The upregulation of calpain, ", "tBid", " and caspase-3 activity were further inhibited by treatment with ", "EGTA", " in the presence of ALD."], "h": {"pos": [1, 2], "type": null, "name": "tBid  and caspase-3 activity were further inhibited by treatment with "}, "t": {"pos": [3, 4], "type": null, "name": "EGTA  in the presence of ALD."}}
{"relation": "INDIRECT-DOWNREGULATOR", "token": ["", "Dexamethasone", " (DXM) decreased the expression of ", "CXCL-8", ", VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS."], "h": {"pos": [1, 2], "type": null, "name": "Dexamethasone  (DXM) decreased the expression of "}, "t": {"pos": [3, 4], "type": null, "name": "CXCL-8 , VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS."}}
{"relation": "INDIRECT-DOWNREGULATOR", "token": ["INTRODUCTION: The principal aim of this study was to assess the efficacy of ", "quinidine", " in suppressing ", "IKr", " in vitro and in modulating the rate dependence of the QT interval in the \"SQT1\" form of the short QT syndrome."], "h": {"pos": [1, 2], "type": null, "name": "quinidine  in suppressing "}, "t": {"pos": [3, 4], "type": null, "name": "IKr  in vitro and in modulating the rate dependence of the QT interval in the \"SQT1\" form of the short QT syndrome."}}
{"relation": "ACTIVATOR", "token": ["Moreover, activities of ", "caspase-3", " and caspase-9 enzymes were also significantly higher in both kinds of cells exposed to ", "SiO(2)", " NPs."], "h": {"pos": [1, 2], "type": null, "name": "caspase-3  and caspase-9 enzymes were also significantly higher in both kinds of cells exposed to "}, "t": {"pos": [3, 4], "type": null, "name": "SiO(2)  NPs."}}
{"relation": "ACTIVATOR", "token": ["In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the ", "C2-ceramide", "-induced ", "SRE", " activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus."], "h": {"pos": [1, 2], "type": null, "name": "C2-ceramide -induced "}, "t": {"pos": [3, 4], "type": null, "name": "SRE  activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus."}}
{"relation": "ACTIVATOR", "token": ["", "Indomethacin", " treatment led to an increase in lipid peroxidation, glutathione peroxidase and ", "glucose-6-phosphate dehydrogenase", " activities and to a decrease in catalase activity and glutathione levels in gastric mucosa."], "h": {"pos": [1, 2], "type": null, "name": "Indomethacin  treatment led to an increase in lipid peroxidation, glutathione peroxidase and "}, "t": {"pos": [3, 4], "type": null, "name": "glucose-6-phosphate dehydrogenase  activities and to a decrease in catalase activity and glutathione levels in gastric mucosa."}}
{"relation": "ACTIVATOR", "token": ["In addition, PSE inhibited the transcriptional activity of NFAT without interfering with the ", "calcium", "-induced ", "NFAT", " dephosphorylation event, which represents the major signaling pathway for its activation."], "h": {"pos": [1, 2], "type": null, "name": "calcium -induced "}, "t": {"pos": [3, 4], "type": null, "name": "NFAT  dephosphorylation event, which represents the major signaling pathway for its activation."}}
{"relation": "AGONIST-ACTIVATOR", "token": ["RESULTS: ", "DRF 2655", " showed concentration-dependent transactivation of PPARalpha and ", "PPARgamma", "."], "h": {"pos": [1, 2], "type": null, "name": "DRF 2655  showed concentration-dependent transactivation of PPARalpha and "}, "t": {"pos": [3, 4], "type": null, "name": "PPARgamma ."}}
{"relation": "AGONIST-INHIBITOR", "token": ["Pretreatment of the tissues with combined 5-HT1/", "5-HT2", " antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of ", "epinastine", " on the noncholinergic contraction."], "h": {"pos": [1, 2], "type": null, "name": "5-HT2  antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of "}, "t": {"pos": [3, 4], "type": null, "name": "epinastine  on the noncholinergic contraction."}}
{"relation": "SUBSTRATE_PRODUCT-OF", "token": ["Type 2 11\u03b2-hydroxysteroid dehydrogenase encoded by the ", "HSD11B2", " gene converts cortisol to inactive ", "cortisone", ", and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids."], "h": {"pos": [1, 2], "type": null, "name": "HSD11B2  gene converts cortisol to inactive "}, "t": {"pos": [3, 4], "type": null, "name": "cortisone , and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids."}}
